The cash flow from current operations was negative in the amount of TSEK 13,054 (9,643).
The gross margin was 65.3% (70.6%).
Electrode sales volume increased by 19% and was 11,330 (9,550) units. Repeat sales of electrodes to existing customers increased by 23%.
The half year in figures
Net sales were TSEK 10,234 (7,987), +28%.
The loss after tax was TSEK 22,258 (18,948).
The loss per share was SEK 0.31 (0.28).
The cash flow from current operations was negative in the amount of TSEK 16,805 (20,155).
The gross margin was 67.0% (66.4%).
Electrode sales volume increased by 17% and was 22,944 (19,580) units. Repeat sales of electrodes to existing customers increased by 1%.
Important events during the quarter
Overall sales increased by 36% (+24, before currency effects). Sales in Germany increased by 62% (48% in local currency). Sales in the US skin cancer market were 74% lower than Q2 2022. Sales within the skin barrier segment decreased by 18%.
Two Medicare Administrative Contractors (MACs): First Coast Service Options (First Coast) and Novitas Solutions (Novitas) released updated fee schedules for SciBase's early detection test for melanoma. First Coast covers the state of Florida and Novitas covers the central and mid-Atlantic US and together they cover about one-third of the US Medicare population. The fee schedules have been increased to levels seen as more appropriate by clinicians.
The current CEO Simon Grant announced he will leave his position as CEO for personal reasons.
The AGM 2023 was held on May 17th.
The annual report for 2022 was published.
Important events after the end of the period
No events of significant nature have occurred after the end of the period.
Financial overview
July 1, 2022 -
Apr 1 - June 30
Jan 1 - June 30
June 30, 2023
Jan 1 - Dec 31
THE GROUP
2023
2022
2023
2022
Rolling-12
2022
Net sales, SEK ths
5 085
3 726
10 234
7 987
20 137
17 890
Gross margin, %
65,3 %
70,6 %
67,0 %
66,4 %
63,5 %
62,8 %
Equity/Asset ratio, %
73,7 %
76,6 %
73,7 %
76,6 %
74,9 %
50,6 %
Net indebtness, multiple
0,36
0,30
0,36
0,30
0,34
0,98
Cash equivalents, SEK ths
70 874
44 577
70 874
44 577
70 874
18 832
Cashflow from operating activities, SEK ths
-13 054
-9 643
-16 805
-20 155
-41 116
-44 466
Earnings per share (before and after dilution), SEK
-0,16
-0,13
-0,31
-0,28
-0,67
-0,63
Shareholder's equity per share, SEK
0,60
0,72
0,75
0,72
0,74
0,37
Average number of shares, 000'
119 831
68 475
96 129
68 475
82 302
68 475
Number of shares at closing of period, 000'*
119 831
68 475
119 831
68 475
119 831
68 475
Share price at end of period, SEK
1,19
3,41
1,19
3,41
1,19
3,82
Number of sold electrodes, pieces
11 330
9 550
22 944
19 580
45 076
41 712
Average number of employees
22
19
21
19
21
20
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was originally submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 18, 2023.
This interim report report has not been subject to review by the Company's auditors
Contact person: Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact: Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email: [email protected]
About SciBase and Nevisense SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com. All press-releases and financial reports can be found here : http://investors.scibase.se/en/pressreleases
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...